Department of Anesthesia, Sree Balaji Medical College and Hospital, Chennai-600044, Tamilnadu, India.
Propofol ,critically ill patients ,ICU ,Anesthesia ,

Propofol (2, 6-diisopropylphenol) is a flexible, potent, short-acting intravenous sedative-hypnotic agent commonly used in the intensive care unit to provide sustained sedation for intubated, mechanically ventilated patients (ICU). Rapid onset of action, rapid rate of distribution, dose-related hypnotic effect, rapid clearance, enhanced patient comfort, healthy pharmacologic profile, immunomodulatory activity, and anti-inflammatory properties are all proposed benefits of propofol sedation. However, propofol use has been linked to adverse reactions and drug-related incidents. The aim of this research was to know whether preservative-free propofol infusion has an independent effect on outcome. Patients receiving propofol had a higher incidence of ICU-acquired infection (50 percent vs 35.3 percent; P 5.003), a trend toward lower ICU mortality (10.5 percent vs 16.8 percent; P 5.09), and slightly lower hospital mortality (17.7% vs 33.3 percent; P 5.0009). However, there were no major differences in ICU or hospital LOS between groups. Preservative-free propofol infusion is linked to an increased risk of ICU-acquired infections and sepsis, but not to an increased risk of ICU or hospital mortality. More research is required to confirm our findings and see if preservative-containing propofol formulations, such as EDTA propofol or the water-soluble pro-drug of propofol (fospropofol), are associated with a lower risk of infection than preservative-free propofol.

6 , 2 , 2016